(J Clin Endocrinol Metab 78: 922-927,1994) H UMAN pituitary tumors represent between 8-10% of all intracranial neoplasms, virtually all of which are benign adenomas of the anterior pituitary gland (1). Although the molecular pathogenesis of pituitary tumors remains largely unknown, there has been increasing interest in defining the types of genetic alterations that may contribute to human pituitary tumorigenesis (2,3). Molecular genetic approaches using X-chromosomal inactivation analysis have shown that the majority of pituitary tumors are monoclonal in origin, suggesting that neoplastic transformation results from one or more somatic mutations of a single progenitor cell, as occurs in most forms of neoplasia (4-8). Somatic mutations may either activate protooncogenes and/or inactivate tumor suppressor genes, leading to expression of the neoplastic phenotype (9).
Such a somatic mutation has been identified in a subset of GH-secreting adenomas. Point mutations in the a-subunit of the G, protein (the stimulatory regulatory protein of adenylyl cyclase) are found in approximately 40% of these tumors and are thought to convert G, a-subunit into a putative oncogene termed gsp (10-12). Mutations in the YUS genes, which encode for GTP-binding proteins that are structurally similar to the G, a-subunit, are frequently detected in lung and colon cancers, but are uncommon in the majority of pituitary tumors (2, 3, 13). The hst oncogene, a member of the fibroblast growth factor family, has been implicated as a transforming gene in two prolactinomas using an NIH/3T3 cell tumorigenicity assay in nude mice (14) . Other studies screening for genetic alterations in human pituitary tumors have failed to identify mutations in several known oncogenes and in the p53 tumor suppressor gene (2, 3).
Recent studies in mice have implicated a possible role for the retinoblastoma tumor suppressor gene (RBl) in the pathogenesis of pituitary tumors. A high percentage of transgenic heterozygous mice containing one disrupted RBl allele have been shown to develop pituitary tumors (15). Pituitary tumors have also been observed in transgenic mice containing the simian virus-40 and polyoma virus large T-antigens (16, 17), both of which are known to complex with and possibly inactivate the RB protein (18, 19) . RBl was the first identified tumor-suppressor gene (20) and is one of the best studied in the growing list of tumor suppressor genes. Besides its inactivation during the genesis of both hereditary and sporadic forms of retinoblastoma, somatic mutations in RBl are found in a proportion of other sporadic tumors, including mesenchymal, epithelial, hematological, and glial neoplasms (21- of 10 wg/mL to the homogenized tissue. The subsequent procedures are the same as those previously described (34). The DNA separated as a band above the RNA pellet in the cesium chloride gradient and could be visualized and isolated under UV light. The DNA was then dialyzed and digested with sodium dodecyl sulfate-proteinase-K, followed by phenol-chloroform extractions, and finally dialyzed against diluted TE buffer (10 mmol/L Tris, pH 8.0, and 0.1 mmol/L ethylenediaminetetraacetic acid). The RNA pellet is processed in a separate manner and was not used in the present study.
PCR, primers, and clonality assay
For PCR with RB1.20, 100 ng genomic DNA were amplified with 20 pmol of each primer (857, 5'-TGTATCGGCTAGCCTATCTC-3'; B103, 5'-AATTAACAAGGTGTGGTGGT-3').
0.2 mmol/L of each deoxv-NTP, 5 FL 10 X amplification buffer [Ib X = 0.5 mol/L KCl, 0.2 moljL Tris (pH 8.6), 1 pg/rL BSA, and 15 mmol/L MgCl,], and 0.5 U Taq polymerase (Perkin-Elmer, Norwalk, CT) in 50 PL. The PCR reaction was carried out with initial denaturation at 94 C for 5 min, followed by 34 cycles of 94 C for 1 min, 52 C for 1 min, and 71 C for 1 min, and a final extension of 5 min at 71 C. 
Quantitation and determination of clonality ratio (CR)
To obtain precise determination of the ratio between the two X-linked alleles generated by the HUMARA clonality assay, the same gel after film autoradiography (Fig. 3 ) was exposed to a I'hophorImager screen (Molecular Dynamics, Eugene, OR), and the intensity of each allele was measured with the ImageQuant software.
The clonality of each tumor was determined by the CR using the following procedure. First, the corrected tumor ratio (ctr) was calculated by the formula:
, where a/b is the band intensity ratio of the upper band over the lower band with HpaII precut tumor sample, and c/d is the band intensity ratio of the upper band over the lower band of the control (nonprecut) tumor sample. This corrected ratio compensates for any potential preferential amplification of one of the two alleles in the PCR reaction. In fact, it has been observed that in some clonal samples the allele that resides on the active X-chromosome is more easily amplified than the allele on the inactive X-chromosome. This phenomenon is easily observed in the nonprecut sample where both the active and inactive Xalleles are amplified (Busque, L., and D. Gilliland, manuscript in preparation).
We analyzed noninvolved tissue (DNA from blood leukocytes) for each patient to control for Lyonization (37), because skewing toward one allele to an extent that meets criteria for clonal derivation may be as high as 25% of normal females (38, 39). The Lyonization ratio or corrected blood ratio (cbr) for blood samples was calculated by the same formula as the ctr. Finally, the CR was obtained by the following formula: CR = ctr/cbr or cbr/ctr, whichever is greater than 1. This CR corresponds to the deviation from the original Lyonization ratio of the individual female caused by clonal cells contained in the tumor sample. With those stringent criteria for clonality assay, a polyclonal sample will have a CR close to 1 and a sample containing an appreciable number of clonal cells (>50%)
will have a CR greater than 3.
Results
We studied 34 pituitary adenomas (Table 1) for LOH within the RBl locus using a PCR-based microsatellite polymorphic marker (RB1.20) (30). A PCR-based microsatellite marker was chosen for this study because it requires small amounts of DNA for analysis and is an extremely informative marker for LOH analysis. In the 21 cases with matched blood (PTI-PT21), 18 cases were heterozygous for the marker, and no LOH was observed in tumors (Fig. 1) . A matched tumor/ blood pair from a RB patient (case 387) did show a loss of one allele in the tumor (Fig. 1) . In 3 of 21 cases (PT3, PT15, and PT17), there was a single band seen in both the tumor and the blood DNA, making these cases uninformative, as shown in Fig. 1 for PT3 (data not shown for PT15 and PT17). Table 1 . In cases 2,6, and 13, two bands in both blood and tumor are evident in the original autoradiogram.
In the 13 cases without matched blood (PT22-34), the high crosatellite marker (RB1.20), we chose to analyze 14 tumors frequency of heterozygosity of the RB1.20 marker allowed interpretation of 12 cases. Because 2 bands (heterozygous) were observed in these 12 tumors, it can be inferred that there is no LOH occurring in tumor DNA (data not shown). In the remaining case (PT34), a single band was observed, which was not interpretable without corresponding constitutional DNA (data not shown). Therefore, in a total of 30 informative cases, there was no LOH observed in tumor samples. No size alterations in the repeat, which might suggest microsatellite instability, were noted between matched tumor and blood DNA samples.
To confirm the results obtained with the PCR-based mifor which sufficient DNA was available, using more conventional Southern blot analysis with a VNTR polymorphic probe (p68RS2.0) from the RBl gene (31). In 8 of 14 tumors, 2 bands were clearly identified (heterozygous) in the blood, and in none of the 8 cases was LOH identified in the corresponding tumors, whereas LOH was observed in the tumor of a RB patient (case 387; Fig. 2 ). Normal tissues intermixed within tumor samples can potentially obscure LOH analysis with PCR-based markers, given the high sensitivity of the PCR reaction. In the present study, special care was taken to exclude normal tissue from samples that were snap-frozen. We confirmed the purity of screen. Labeling was carried out as described in Fig. 1 . KB, Kilobases.
B, Blood; T, tumor.
tumor samples using a recently described PCR-based clonality analysis with a microsatellite polymorphic marker within the human androgen receptor gene (HUMARA) on the X-chromosome (32). As the majority of pituitary adenomas have been shown to be monoclonal in origin (4-8), if normal tissues are present in sufficient quantity, a monoclonal pattern might be obscured (40). In the present study, five representative tumors from female patients with matched blood were used to assess clonality using this assay, and the results are shown in Fig. 3 . In four cases (PT2, PT3, PT7, and PT13), a monoclonal pattern in tumors was observed with CR values of 7.63, 4.17, 3.35, and 31.7, respectively. In PTIO, a mixed GH/PRL-secreting adenoma, a polyclonal pattern was detected, with a CR value of 1.05. A polyclonal pattern has previously been reported in mixed GH/PRL-secreting adenomas (6). This suggests that the tumor may be polyclonally derived, that it contained two clonal populations of opposite alleles, or that a substantial amount of normal cells (>80%) was present in the tumor. The study of large numbers of mixed tumors and/or plurihormonal tumors may serve to clarify this finding. A normal anterior pituitary gland from a female patient was used as a control specimen and was found to be polyclonal with an allelic ratio of 1.72, compatible with moderate Lyonization. These findings confirm monoclonality in 4 of 5 of the selected pituitary adenomas and illustrate concurrently a monoclonal pattern and no LOH at the RBl locus in these tumors.
Discussion
The majority of human pituitary tumors are benign monoclonal neoplasms, suggesting that somatic mutations in a 
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